Granules Pharmaceuticals Inc. announced the FDA approval of its ANDA for Hydrocodone Bitartrate and Acetaminophen, granting the company a strategic entry into the established analgesic market. This approval is expected to stimulate competition and bolster Granules' revenue growth potential within the widely prescribed pain management sector.